Category: Brandpoint

2023-12-07T15:01:00

(BPT) – It’s that time of year again — time to assess some important life maintenance duties to prepare for the year ahead, starting with your annual health care benefits review for both you and your family. Whether you have an employer-sponsored plan or individual coverage for medical, dental and vision, the end of one year and the beginning of another is a great time to evaluate your health care options and assess your insurance needs. And while you’re at it, it’s also the perfect time to set an annual reminder to check a few other life duties off your busy to-do list.

1. Take time to fully take stock

Consider dedicating a day to take stock of your family’s health and financial situation, then make a list of any tasks you may need to complete to accommodate these changes. Getting your ideas on paper can be immensely helpful for tackling and prioritizing to-do lists while avoiding feeling overwhelmed.

For starters, as you review your employer’s health insurance plans (or Medicare plans, if you’re now eligible), it’s important to ensure that your current health care plans cover your needs in terms of level of coverage, prescriptions, wellness visits, etc. — all at a cost that’s affordable for you and your family.

Next, consider what other crucial life administration tasks can contribute to your overall security and peace of mind. For example, when was the last time you reviewed your homeowners or auto insurance? If you’ve had changes to your circumstances over the past few years, it’s recommended that you review your needs, benefits and costs to make sure your current plans make sense, and that you’re sufficiently covered in case of emergencies or unforeseen events.

This is also the perfect time of year to think about estate planning or review whether you have other important documents in place, such as a will. Families and situations change over time, so it’s important to be sure your estate plan is up to date.

2. Make time for your eye health

While eye care is critical to your overall well-being, it is often overlooked when considering health insurance coverage. It’s important to know that a VSP^® Individual Vision Plan can supplement your health care coverage to fill in gaps that may exist in other plans. And best yet, you can purchase a VSP Individual Vision Plan any time — not just during open enrollment season.

VSP plans start as low as $13 per month and can help you save up to $300 per year, while also giving you access to the largest independent eye doctor network. Plans include 30% savings on lens enhancements, like progressives from the VSP network of eye doctors, plus members get access to benefits like 20% savings on additional glasses or sunglasses within 12 months of your last exam.

Because you can enroll in a VSP Individual Vision Plan at any time, you’re even covered if you miss the open enrollment period. You can sign up for new vision care coverage 24/7/365, with coverage starting the same day you apply. Find out which vision plan is best for you at VSPDirect.com.

3. Schedule annual appointments and household maintenance

The end of the year is a great time to prioritize vital tasks such as getting your routine health care appointments completed (especially if you haven’t utilized your benefits for the year); winterizing your car; and completing (or hiring experts for) household maintenance jobs like gutter cleaning, pest control/inspections, energy audits and routine HVAC servicing.

Many also put reminders on their calendars for this time of year to tackle annual or semi-annual tasks such as swapping out batteries in household smoke and carbon monoxide detectors. The colder weather and the holiday season also provide a great excuse to clean out your closets, then donate old clothes and other items in good condition to local charities.

By taking care of these essential matters on a regular annual schedule, you can rest assured that your household tasks and health care plans are in place as the new year gets underway.

2023-12-07T10:03:00

(BPT) – In August 2017, Sarah and her family had plans to join relatives in Arizona for a fun-filled few days of off-roading and watching the solar eclipse. The Monday before she left, Sarah woke up in the middle of the night with nearly uncontrollable rigors (also known as shaking chills) and was barely able to walk. She felt better – although fatigued – the next day, but after two more similar episodes, Sarah went to urgent care, hoping for answers to what was going on. Sarah was diagnosed with a urinary tract infection, and, after receiving an ultrasound and a prescription for antibiotics, Sarah and her family drove to Arizona for their vacation, completely unaware that there may be a more serious problem with her health.

“The doctor started calling just as we crossed over the border into Arizona, leaving messages and repeatedly calling back,” Sarah recalled. “When we got to our destination, we called with my entire family in the room. The doctor said I needed to get to the hospital immediately. We asked if we could go after we saw the eclipse, and the doctor said, ‘No – she won’t live that long.’”

Rushing back to the hospital, the doctor told Sarah that her ureter, the duct connecting the bladder and kidneys, had collapsed, she had sepsis (an infection of the bloodstream that may occur as a complication of an infection) and she needed emergency surgery to have a stent put in immediately. Sarah underwent surgery and over the next several months, she continued to receive antibiotics. That December, Sarah met with the head of the hospital’s urology department and an oncologist who informed her that she had transitional cell carcinoma, also known as urothelial cancer – the most common type of bladder cancer.

ABOUT BLADDER CANCER

Bladder cancer primarily affects older people. In fact, approximately nine out of 10 people with this type of cancer are over the age of 55, and the average age of diagnosis is 73 years.[1] In 2023, there were approximately 82,290 new cases of bladder cancer and approximately 16,710 deaths estimated to be reported in the U.S.[2] It is the fourth most common cancer among men in the U.S. and for men, the likelihood for developing bladder cancer during their life is about 1 in 27.[1] For women, the probability of developing bladder cancer during their life is lower at about 1 in 89.[1] Urothelial cancer, or cancer that occurs within the urothelial cells, which line the urethra, bladder, ureters, and renal pelvis, accounts for about 90% of bladder cancers.[3] In addition to its cell type, bladder cancer may be described as non-muscle-invasive or muscle-invasive.[3] If bladder cancer has spread to surrounding organs or tissues, it is called locally advanced disease. If the cancer has spread to other parts of the body, it is called metastatic disease.[3]

BLADDER CANCER SYMPTOMS

Bladder cancer is a disease in which cells within the bladder begin to grow out of control, form a tumor and, with time, may spread to other parts of the body.[4] It is often associated with urinary symptoms and other symptoms that can negatively impact a person’s quality of life.[5] Oftentimes, bladder cancer can be diagnosed early because symptoms like blood in the urine, changes in bladder habits or symptoms of irritation may prompt a person to consult their healthcare provider.[5] In some cases though, the symptoms may mirror other conditions – such as the urinary tract infection Sarah was originally diagnosed with – which can delay a bladder cancer diagnosis.[5]

Many people living with bladder cancer experience symptoms that include:[5]

• blood in the urine
• changes in bladder habits, such as having to urinate more often than usual
• pain or burning during urination
• feeling as if you need to urinate right away, even when your bladder isn’t full
• having trouble urinating or having a weak urine stream
• or having to get up to urinate many times during the night

Other people experience symptoms such as pain, tiredness, loss of appetite or weight loss.[5]

SARAH’S TREATMENT JOURNEY

Sarah was initially treated with chemotherapy. By June 2018, the cancer had spread, and surgeons eventually needed to remove her ureter, one kidney and 17 lymph nodes.

“After the surgery, I thought I was doing great. I really thought I was getting a lot better, but I started noticing that I was a little short of breath and still had some fatigue,” Sarah noted.

Through routine follow up, her doctors discovered that Sarah had a small nodule on her lung. A biopsy revealed that the nodule was malignant and that the cancer had continued to spread.

Leaning on her husband, a minister, and her faith, as well as adopting “Fight On!” – the official fight song of her favorite football team, the University of Southern California Trojans – as her mantra, Sarah decided that she “was going to choose life, and I was going to fight on.”

Following her doctor’s recommendation, Sarah joined a clinical study investigating the safety and effectiveness of a treatment called PADCEV® (enfortumab vedotin-ejfv) in combination with an immunotherapy drug. PADCEV is a medication known as an antibody-drug conjugate or ADC that works by delivering cell-killing medicine directly to certain cancer cells.[6] PADCEV may be used with pembrolizumab (Keytruda®) for adults with advanced bladder cancer who are not able to receive a chemotherapy that contains the medicine cisplatin. PADCEV with pembrolizumab was FDA approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab to confirm this clinical benefit. PADCEV may also be used as monotherapy for adults with advanced bladder cancer who have received an immunotherapy medicine and chemotherapy that contains platinum, or who are not able to receive a chemotherapy that contains the medicine cisplatin and have received one or more prior therapies.[7]

PADCEV may cause serious side effects including skin reactions. Severe skin reactions have happened in people treated with PADCEV, and in some cases, severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. People who are treated with PADCEV will be monitored during treatment by their healthcare providers who may stop their treatment with PADCEV completely or for a period of time (temporarily), or may change their dose, or prescribe medicines if they get skin reactions. Please see Important Safety Information below and read the Patient Information for more information, including risk of Serious Side Effects.

After Sarah enrolled in the clinical trial and began treatment with PADCEV and pembrolizumab, she was often fatigued and developed a severe rash, particularly on her legs and feet. She was on the treatment for a total of 14 months.

In a clinical trial of 121 adults treated with PADCEV in combination with pembrolizumab, who were previously untreated and could not receive cisplatin-containing chemotherapy, 55% of patients had a partial response, meaning that their tumors shrank, and 12% of patients had a complete response, meaning their tumors disappeared.[7] Individual results may vary.

Now, more than a year after completing treatment with PADCEV in combination with pembrolizumab, Sarah’s cancer is in remission. Her fatigue has resolved, however, she still deals with skin issues, and experiences weakness, numbness, pain and muscle loss in her hands and feet. Despite it all, Sarah remains grateful for the support of her church, her family and her entire community who have rallied around her during this difficult time.

“My message to other people going through a similar experience is ‘don’t let cancer define you, and don’t be afraid of it,’” Sarah says. “I really believe you can face cancer – don’t see yourself as a victim. All you have is today. I want to end each day saying, I have no regrets for this day that I’ve lived today.”

Cancer has impacted Sarah’s life in many ways, including limiting her ability to participate in some activities she previously enjoyed. She still loves to go off-roading, but these days she and her husband opt for the gentler roads. Sarah recalls, “Before I had cancer, our kids told us that I was more active than they were. After the cancer, I’m happy to say that I don’t think I’ve slowed down a whole lot.”

Sarah was compensated by Astellas and Seagen to share her story. This was her experience at the time of publication. Please see Important Safety Information below and read the Patient Information for more information, including risk of Serious Side Effects.

If you or someone you love has bladder cancer, visit https://padcev.com/ for more information, resources and support.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about PADCEV?

PADCEV may cause serious side effects, including:

Skin reactions. Skin reactions including severe skin reactions have happened in people treated with PADCEV and may be more common when PADCEV is given with pembrolizumab. In some cases, these severe skin reactions have caused death. Most severe skin reactions occurred during the first cycle of treatment but may happen later. Your healthcare provider will monitor you, may stop your treatment with PADCEV completely or for a period of time (temporarily), may change your dose, and may prescribe medicines if you get skin reactions. Tell your healthcare provider right away if you develop any of these signs of a new or worsening skin reaction:

target lesions (skin reactions that look like rings) rash or itching that continues to get worse blistering or peeling of the skin

painful sores or ulcers in mouth or nose, throat, or genital area fever or flu-like symptoms swollen lymph nodes

See “What are the possible side effects of PADCEV?” for more information about side effects.

Before receiving PADCEV, tell your healthcare provider about all of your medical conditions, including if you:

• are currently experiencing numbness or tingling in your hands or feet.
• have a history of high blood sugar or diabetes.
• have liver problems.
• are pregnant or plan to become pregnant. PADCEV can harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with PADCEV.
• are breastfeeding or plan to breastfeed. It is not known if PADCEV passes into your breast milk. Do not breastfeed during treatment and for at least 3 weeks after the last dose of PADCEV.

Females who are able to become pregnant:

• Your healthcare provider should do a pregnancy test before you start treatment with PADCEV.
• You should use an effective method of birth control during your treatment and for at least 2 months after the last dose of PADCEV.

Males with a female sexual partner who is able to become pregnant:

• If your female partner is pregnant, PADCEV can harm the unborn baby.
• You should use an effective method of birth control during your treatment and for at least 4 months after the last dose of PADCEV.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking PADCEV with certain other medicines may cause side effects.

What are the possible side effects of PADCEV?

PADCEV may cause serious side effects, including:

• Skin Reactions. See “What is the most important information I should know about PADCEV?”
• High blood sugar (hyperglycemia). An increase in blood sugar is common during treatment with PADCEV. Severe high blood sugar, a serious condition called diabetic ketoacidosis (DKA), and death have happened in people with and without diabetes treated with PADCEV. Tell your healthcare provider right away if you have any symptoms of high blood sugar, including: frequent urination, increased thirst, blurred vision, confusion, it becomes harder to control your blood sugar, drowsiness, loss of appetite, fruity smell on your breath, nausea, vomiting, or stomach pain.
• Lung problems. PADCEV may cause severe or life-threatening inflammation of the lungs that can lead to death. These severe problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening symptoms, including trouble breathing, shortness of breath, or cough.
• Nerve problems. Nerve problems called peripheral neuropathy are common during treatment with PADCEV and can sometimes be severe. Nerve problems may happen more often when PADCEV is given in combination with pembrolizumab. Tell your healthcare provider right away if you get new or worsening numbness or tingling in your hands or feet or muscle weakness.
• Eye problems. Certain eye problems are common during treatment with PADCEV. Tell your healthcare provider right away if you have dry eyes, increased tearing, blurred vision, or any vision changes. You may use artificial tear substitutes to help prevent or treat dry eyes.
• Leakage of PADCEV out of your vein into the tissues around your infusion site (extravasation). If PADCEV leaks from the injection site or the vein into the nearby skin and tissues, it could cause an infusion site reaction. These reactions can happen right after you receive an infusion, but sometimes may happen days after your infusion. Tell your healthcare provider or get medical help right away if you notice any redness, swelling, itching, blister, peeling skin or discomfort at the infusion site.

Your healthcare provider may decrease your dose of PADCEV, or temporarily or completely stop your treatment with PADCEV if you have severe side effects.

The most common side effects of PADCEV when used alone include:

rash. See “What is the most important information I should know about PADCEV?” changes in liver and kidney function tests increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)” tiredness decreased white blood cell, red blood cell, and platelet counts

hair loss decreased appetite diarrhea decreased sodium, phosphate and protein (albumin) in the blood nausea

itching change in sense of taste increased uric acid in the blood increased lipase (a blood test done to check your pancreas) decreased weight dry skin

If your healthcare provider prescribes PADCEV in combination with pembrolizumab for you, also read the Medication Guide that comes with pembrolizumab for important information about pembrolizumab.

The most common side effects of PADCEV when used in combination with pembrolizumab include:

increased sugar (glucose) in the blood. See “High blood sugar (hyperglycemia)” changes in liver function and kidney function tests rash. See “What is the most important information I should know about PADCEV?” decreased red blood cell and white blood cell counts tiredness decreased sodium, phosphate and protein (albumin) in the blood increased lipase (a test done to check your pancreas)

hair loss decreased weight diarrhea itching decreased appetite nausea change in sense of taste urinary tract infection constipation increased or decreased potassium

increased calcium in the blood swelling of the arms, hands, legs and feet dry eye. See “Eye problems” dizziness joint aches dry skin

PADCEV may cause fertility problems in females and males, which may affect the ability to have children. Talk to your healthcare provider if you have concerns about fertility.

These are not all the possible side effects of PADCEV.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

WHAT IS PADCEV®?

PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used alone if you:

• have received an immunotherapy medicine and chemotherapy that contains platinum, or
• are not able to receive a chemotherapy that contains the medicine cisplatin and you have received 1 or more prior therapy.

PADCEV may be used with pembrolizumab (also known as Keytruda^®) if you:

• are not able to receive a chemotherapy that contains the medicine cisplatin.

PADCEV with pembrolizumab was FDA-approved based on a clinical study that measured how many people had a tumor response. There is another study of PADCEV with pembrolizumab ongoing to confirm the clinical benefit.

It is not known if PADCEV is safe and effective in children.

^© 2023 Astellas Pharma US, Inc. and Seagen Inc. All rights reserved. 081-2074-PM 11/23

PADCEV and the PADCEV device are registered trademarks jointly owned by Agensys, Inc., and Seagen Inc.

Keytruda^® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

1. American Cancer Society. Key Statistics for Bladder Cancer (01-13-2023). https://www.cancer.org/cancer/types/bladder-cancer/about/key-statistics.html. Accessed 6-27-2023.
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17-48
3. American Society of Clinical Oncology. Bladder Cancer: Introduction (12-21). https://www.cancer.net/cancer types/bladdercancer/introduction. Accessed 7-14-2023.
4. American Cancer Society. What Is Bladder Cancer? (12-19-2019). https://www.cancer.org/cancer/bladder cancer/about/whatisbladdercancer.html. Accessed 9-27-2023.
5. American Cancer Society. Bladder Cancer Signs and Symptoms (01-30-2019). https://www.cancer.org/cancer/types/bladder-cancer/detection-diagnosis-staging/signs-and-symptoms.html Accessed 10-20-2022.
6. National Cancer Institute. NCI dictionary of cancer terms: antibody-drug conjugate. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate. Accessed 6-27-2023.
7. PADCEV [package insert]. Northbrook, IL: Astellas Pharma US, Inc.

2023-12-07T07:01:00

(BPT) – Stephanie, 38, was on the phone with her grandmother as she sat in traffic making her way from her day job as an administrative assistant to her evening waitressing shift. Suddenly, she felt the urge to drive to the side of the highway and throw up all over the road. She was experiencing symptoms of yet another migraine attack — symptoms she has suffered with since the age of 7.

Her grandmother, still on the phone, begged Stephanie to turn her car around and go home to rest, but Stephanie couldn’t afford to miss work.

Migraine is a disabling neurological disease that affects more than 39 million Americans and can cause debilitating symptoms including throbbing and pulsating pain, blurred vision, sensitivity to light and sound, as well as nausea and vomiting.

“There was a time when my migraine attacks were so bad that I vomited constantly because of the excruciating pain. I had a grayish hue to my skin and a grayish hue to my life,” said Stephanie. “But I work two jobs to help support my family, so I had to push through it as best I could.”

She also often missed family events, going out with friends and was no longer able to attend her yoga classes because of her migraine attacks.

Life got remarkably better for Stephanie once she had more certainty about what she was dealing with — migraine. Diagnosis in hand, she partnered with her neurologist to find a treatment and lifestyle program that has helped her experience more migraine-free days.

“Once I received my diagnosis, I realized how essential it was for me to take care of my body and relieve the stress and anxiety I felt because of migraine,” said Stephanie. “But first, I needed to find a treatment that would work for me.”

After not feeling satisfied in her treatment journey, Stephanie decided to look for a new option to help manage her migraine disease more effectively. She asked her neurologist about VYEPTI^® (eptinezumab-jjmr), a prescription medicine used for the preventive treatment of migraine in adults.

“My neurologist was very supportive and had seen success with other patients trying it,” said Stephanie.

Since her first infusion with VYEPTI, Stephanie has had a decrease in monthly migraine days. In patients with 4 or more migraine days a month, VYEPTI has been proven to reduce monthly migraine days over months 1-3 compared to placebo. Individual results may vary.

Do not receive VYEPTI if you are allergic to eptinezumab-jjmr or any of the ingredients in VYEPTI. See additional Important Safety Information for VYEPTI below.

With more migraine-free days, Stephanie has reconnected with her love of yoga and exercise. With her doctor’s approval, she now practices yoga more regularly. This consistent practice has allowed her to ease back into her other favorite workouts in a sustainable way, despite the unpredictability of migraine. She also has learned what poses tend to help when she feels the onset of a migraine attack. For her, poses like the tree pose have been invaluable tools she can use to reconnect her body and mind to help navigate the pain. Please note, individual experiences may vary. Consult with your healthcare provider before starting any new exercise routine.

These days, Stephanie is enjoying her physical and mental strength through her traditional and aerial yoga practice and participation in a friend’s dance class. “There was a time when I wouldn’t have been able to take her class. With more migraine-free days, I can be more active, which has made it easier for me to navigate the tough days and enjoy the good days.”

For more VYEPTI patient stories and to watch expert-led mind and body practices for people with migraine, including yoga, sound bath and supportive self-care, visit VYEPTI.com.

APPROVED USE
VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Do not receive VYEPTI if you have a known allergy to eptinezumab-jjmr or its ingredients.

VYEPTI may cause allergic reactions. Call your healthcare provider or get emergency medical help right away if you have any symptoms of an allergic reaction: rash; swelling of your face, lips, tongue, or throat; if you have trouble breathing; hives; or redness in your face.

Before starting VYEPTI, tell your healthcare provider about all your medical conditions, including if you are pregnant or plan to become pregnant, or you are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

The most common side effects of VYEPTI include stuffy nose and scratchy throat, and allergic reactions.

These are not all the possible side effects of VYEPTI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For more information, please see the Prescribing Information and Patient Information or go to vyepti.com.

2023-12-05T23:01:00

(BPT) – Former U.S. Congressman Gregg Harper’s son, Livingston, has Fragile X Syndrome (FXS), a rare neurological disease often misdiagnosed as autism or attention deficit/hyperactivity disorder (ADHD). FXS affects 1 in 4,000 boys and 1 in 8,000 girls worldwide¹ and is the most common inherited cause of autism and intellectual disability. At 34 years old, Livingston continues to wait for an FDA-approved therapy to treat his FXS symptoms.

Gregg laments the lack of clinical research when Livingston was first diagnosed at just four years old, “Thirty years ago, I don’t think many pediatricians knew what Fragile X Syndrome was, let alone how to test for it and diagnosis it. There were no clinical trials to even consider.”

He continues, “Today, pediatricians can conduct a simple genetic test for FXS and there are multiple clinical trials underway in hopes of introducing new, effective treatments for this genetic disorder. It’s so important for families to participate in these trials because they may open doors that help our entire FXS community.”

Gregg is also realistic about potential barriers to participation in clinical research for FXS families. Many people with FXS have behavioral symptoms and anxiety that can make trial visits challenging for their caregivers and the individual.

Gregg shares that when his son was young, his wife would take Livingston to speech and occupational therapy and other medical appointments, with his younger sister in tow. “The numerous doctors’ appointments and tests can disrupt the whole family.”

When Gregg learned about a new approach to clinical trials that has emerged allowing for at-home participation, he noted, “that would have been a game changer for our family!”

Science 37, a company that supports at-home clinical trials, keeps the patient at the center of its work by bringing clinical trials directly to them no matter where they live. This helps increase the diversity of trial participants and promotes inclusivity – so important to advancing scientific discovery.

Dr. David Kudrow is the medical director of neurology for the company. “With the Science 37 approach, we can reach patients across the US and not be limited in any way by geographic constraints,” he said. “With our model, you don’t need to sit in the same room as the patient. If an investigator is licensed in the state where the patient lives, we can conduct a study visit.”

Once a patient is screened and enrolled for a clinical trial using telemedicine – appointments by computer, tablet or smartphone – patients and families continue to participate via “virtual” visits.” Additionally, mobile nurses, who are trained and employed by Science 37, visit patients to check vital signs, collect bloodwork and perform other medical evaluations and tests, such as electrocardiograms (ECGs).

As Dr. Kudrow explains, “Children and young adults with FXS don’t have to live near a trial center and caregivers don’t have to miss work or travel with their child to various appointments. On top of that, they still have their entire care team outside of the clinical trial, whom they continue to see for regularly scheduled check-ups. The Science 37 team keeps their care team informed of the trial involvement and progress.”

Dr. Kudrow noted, “With Science 37’s approach and at-home clinical trials like the RECONNECT study, which is currently enrolling, we can reach into any community, support diversity, and go beyond geographic, conventional boundaries to deliver reliable data.”

He concluded: “This is a very special population – not just the kids, but the families. Some families have multiple children with FXS and would otherwise have to travel to a clinical trial site. With respect to convenience, what Science 37 has been able to provide is invaluable. We can go where the patients are.”

Added Gregg: “People should avail themselves of this unique opportunity. I’m excited about it and hope that families who are dealing with FXS realize that we must have participants in these trials to discover new treatments. I urge families to take this opportunity. It’s free, it’s easy and, at the end of the road, it may change lives.”

To learn more about FXS and the ongoing RECONNECT clinical trial of an investigational treatment, visit FragileXHelp.com for more information.

Content sponsored and provided by Harmony Biosciences/Zynerba Pharmaceuticals, Inc. Gregg Harper has partnered with Zynerba to increase awareness of FXS and highlight the vital role of clinical trials in discovering and studying new investigational treatments for rare diseases.

+++

1. https://fragilex.org/understanding-fragile-x/fragile-x-101/